220 related articles for article (PubMed ID: 31780812)
41. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL; Warsame R; Gertz MA; Buadi FK; Lacy MQ; Kumar SK; Dingli D; Zeldenrust SR; Leung N; Hayman SR; Kapoor P; Gonsalves WI; Kourelis TV; Russell S; Go RS; Hobbs MA; Fonder AL; Rajkumar SV; Dispenzieri A
Blood; 2017 Sep; 130(13):1578-1584. PubMed ID: 28807981
[TBL] [Abstract][Full Text] [Related]
42. Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis.
Leguit RJ; Vink A; de Jonge N; Minnema MC; Oerlemans MIF
Cardiovasc Pathol; 2021; 53():107348. PubMed ID: 34038803
[TBL] [Abstract][Full Text] [Related]
43. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.
Sidana S; Milani P; Binder M; Basset M; Tandon N; Foli A; Dispenzieri A; Gertz MA; Hayman SR; Buadi FK; Lacy MQ; Kapoor P; Leung N; Rajkumar SV; Merlini G; Palladini G; Kumar SK
Blood Cancer J; 2020 Apr; 10(4):41. PubMed ID: 32286270
[TBL] [Abstract][Full Text] [Related]
44. [Prognostic factors in light chain amyloidosis].
Jávorniczky NR; Bodó I; Masszi T; Mikala G
Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
[TBL] [Abstract][Full Text] [Related]
45. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival.
Huang XF; Jian S; Lu JL; Shen KN; Feng J; Zhang CL; Tian Z; Wang JL; Lei WJ; Cao XX; Zhou DB; Liang ZY; Li J
Amyloid; 2020 Mar; 27(1):36-44. PubMed ID: 31635489
[No Abstract] [Full Text] [Related]
46. Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management.
Baumgart JV; Stuhlmann-Laeisz C; Hegenbart U; Nattenmüller J; Schönland S; Krüger S; Behrens HM; Röcken C
Virchows Arch; 2018 Nov; 473(5):627-637. PubMed ID: 30136180
[TBL] [Abstract][Full Text] [Related]
47. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
48. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
[No Abstract] [Full Text] [Related]
49. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
50. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
Terrier B; Jaccard A; Harousseau JL; Delarue R; Tournilhac O; Hunault-Berger M; Hamidou M; Dantal J; Bernard M; Grosbois B; Morel P; Coiteux V; Gisserot O; Rodon P; Hot A; Elie C; Leblond V; Fermand JP; Fakhouri F
Medicine (Baltimore); 2008 Mar; 87(2):99-109. PubMed ID: 18344807
[TBL] [Abstract][Full Text] [Related]
51. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.
Hammons L; Brazauskas R; Pasquini M; Hamadani M; Hari P; D'Souza A
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):105-111. PubMed ID: 28830801
[TBL] [Abstract][Full Text] [Related]
52. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.
Sidana S; Sidiqi MH; Dispenzieri A; Buadi FK; Lacy MQ; Muchtar E; Dingli D; Hayman SR; Gonsalves WI; Kapoor P; Leung N; Warsame R; Kourelis TV; Wolf RC; Hogan WJ; Kumar SK; Gertz MA
Am J Hematol; 2019 Sep; 94(9):1020-1026. PubMed ID: 31254301
[TBL] [Abstract][Full Text] [Related]
53. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
54. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
55. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
56. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
[TBL] [Abstract][Full Text] [Related]
57. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
58. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.
Tandon N; Sidana S; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Kyle RA; Buadi FK; Dingli D; Hayman SR; Fonder AL; Hobbs MA; Gonsalves WI; Kapoor P; Hwa YL; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Kumar SK
Amyloid; 2017 Sep; 24(3):183-188. PubMed ID: 28699793
[TBL] [Abstract][Full Text] [Related]
59. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive Review of AL amyloidosis: some practical recommendations.
Al Hamed R; Bazarbachi AH; Bazarbachi A; Malard F; Harousseau JL; Mohty M
Blood Cancer J; 2021 May; 11(5):97. PubMed ID: 34006856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]